23ANDME, INC.

The Precision Medicine market is projected to grow from $89.9B in 2023 to $161.1B by 2030, driven by tech advancements, declining genomic sequencing costs, and personalized treatments. Oncology, chronic diseases, and AI integration are key growth areas.

The global precision medicine market was valued at USD 102.17 billion in 2024, expected to reach USD 470.53 billion by 2034, growing at a CAGR of 16.5%. Precision medicine involves personalized treatments based on genetic, environmental, and behavioral profiles. Key technologies include next-generation sequencing and bioinformatics. The U.S. leads with the NIH's 'All of Us Research Program' and collaborations like AstraZeneca's cancer research. AI tools like Tempus and Foundation Medicine enhance genomic analysis. Potential benefits include improved patient privacy, new data tools, and better FDA oversight. North America dominates the market, with Asia-Pacific expected to grow fastest due to strategic collaborations and government standards.

The precision nutrition market is projected to grow from USD 6.09 billion in 2024 to USD 12.89 billion by 2029, driven by consumer demand for personalized health solutions, genomic research, and chronic disease prevalence. Advanced technologies like AI and data analytics enable customized dietary advice. Europe leads in market share due to developed healthcare infrastructure and government support. Key players include Viome Life Sciences, Prenetics Global, ZOE Limited, and 23andMe.

Global advanced at-home biomarker testing market to grow from USD 1,099.5 million in 2024 to USD 2,255.7 million by 2034 at a CAGR of 7.5%. Driven by preventive healthcare, targeted therapies, and regulatory support, the market faces challenges in sample collection accuracy.

The DNA & RNA Banking Services Market is projected to reach USD 10.92 billion by 2030, driven by advancements in personalized medicine and automated biobanking. Key players include EasyDNA, DNA Genotek, 23andMe, and others. The market is segmented by service, specimen, application, and end-use, with blood specimens and drug discovery applications leading. North America dominates due to precision medicine initiatives.

The Genomics Services Market was valued at USD 6.3 billion in 2023 and is projected to reach USD 17.5 billion by 2032, growing at a CAGR of 11.8% driven by increased investment in genomic research, genetic disorder prevalence, and demand for personalized medicine. Key players include Thermo Fisher Scientific, 23andMe, Agilent Technologies, and Illumina. The market is segmented by services type, technology, application, and end-user, with North America leading in 2023 and Asia-Pacific expected to show high growth.

The global personalized medicine market is projected to grow from USD 530.11 billion in 2023 to USD 1,176.66 billion by 2033, driven by demand for novel drug discovery, collaborations, regulatory support, digital health innovations, and rising prevalence of chronic diseases. Key players include 23andMe, Inc., Abbott Laboratories, and Illumina, Inc., among others.